Effect of Beta-blocker Therapy on QTc Response in Exercise & Recovery in

Status Completed

Clinical Trial Summary

Background. In congenital long QT syndrome type 1 (LQT1), episodes of ventricular tachycardia are usually triggered by exercise and can be prevented in most patients by beta-blocker therapy. In addition, LQT1 associated with a normal resting QT interval can be unmasked by the abnormal QT response to exercise testing (failure of the QT interval to shorten normally). Preliminary data from our laboratory show that the exercise QT intervals of patients with LQT1 are partially normalized by beta-blocker therapy. It is still currently not known if beta-blockers modify the QT/heart rate relationship (a primary effect on repolarization) or if the "normalizing" effect is due to the inability of subjects on beta-blockers to attain sufficiently high workloads (due to reduced heart rate) for prolongation to occur. Moreover, the physiologic response of the exercise QT interval to beta-blockers in healthy control subjects is not known.

Objective. The objective of this study is to define the impact of beta-blocker therapy on the QT response to exercise and recovery in normal subjects.

Methods. Approximately 36 healthy adult subjects age-matched to previously studied LQT1 subjects will undergo 1) screening history, 2) two weeks of beta-blocker therapy ending in an exercise test, and 3) two weeks of placebo therapy ending in an exercise test. Beta blocker and placebo will be given in random order in a double-blind fashion. The QT response to exercise and recovery will be compared between drug-free and beta-blocker-treated states. These data will be compared to those previously collected for LQT1 subjects.

Implications. These results will provide new information about the effect of beta-blocker therapy on repolarization parameters in normal subjects, and will provide a context in which to interpret the previous findings that beta-blocker administration modifies the QT response to exercise in LQT1 subjects.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00588965
Study type	Interventional
Source	MetroHealth Medical Center
Contact
Status	Completed
Phase	N/A
Start date	August 2007
Completion date	December 2008

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04169100` - Novel Form of Acquired Long QT Syndrome	Phase 4
Completed	`NCT01648205` - Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	Phase 2
Recruiting	`NCT06087367` - Building of a Diagnostic/Prognostic Database for Human ERG Variant Effects
Recruiting	`NCT04675788` - Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening	Phase 4
Completed	`NCT05759962` - Phase 1 Study of LQT-1213 in Healthy Adults	Phase 1
Enrolling by invitation	`NCT05903313` - A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
Terminated	`NCT02439645` - A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
Recruiting	`NCT00221832` - Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases	N/A
Completed	`NCT04706104` - QT Measurement Techniques and Anesthesia Management
Recruiting	`NCT04336644` - Continuous Versus Intermittent cARdiac Electrical moNitorinG	N/A
Recruiting	`NCT02814981` - Hydroxyzine and Risk of Prolongation of QT Interval	N/A
Completed	`NCT02425189` - The Canadian National Long QT Syndrome Registry
Completed	`NCT02876380` - Prospective Identification of Long QT Syndrome in Fetal Life
Completed	`NCT00399412` - ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients	N/A
Completed	`NCT02513940` - Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes	Phase 4
Completed	`NCT02441829` - Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function	Phase 1
Completed	`NCT03182777` - Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies	N/A
Completed	`NCT01849003` - Study of the Effect of GS-6615 in Subjects With LQT-3	Phase 1
Completed	`NCT00316459` - Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects	Phase 1
Completed	`NCT00292032` - Registry of Unexplained Cardiac Arrest

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms